Cargando…
Hepatitis C virus genotype 3: clinical features, current and emerging viral inhibitors, future challenges
Hepatitis C virus (HCV) represents a global burden on healthcare that affects over 150 million people worldwide. In the past, HCV genotype 3 was considered difficult to treat relative to other genotypes. Genotype 3 has been associated with a higher rate of complications, including fatty liver diseas...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hellenic Society of Gastroenterology
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6102453/ https://www.ncbi.nlm.nih.gov/pubmed/30174390 http://dx.doi.org/10.20524/aog.2018.0281 |
_version_ | 1783349166601142272 |
---|---|
author | Shahnazarian, Vahe Ramai, Daryl Reddy, Madhavi Mohanty, Smruti |
author_facet | Shahnazarian, Vahe Ramai, Daryl Reddy, Madhavi Mohanty, Smruti |
author_sort | Shahnazarian, Vahe |
collection | PubMed |
description | Hepatitis C virus (HCV) represents a global burden on healthcare that affects over 150 million people worldwide. In the past, HCV genotype 3 was considered difficult to treat relative to other genotypes. Genotype 3 has been associated with a higher rate of complications, including fatty liver disease, fibrosis, hepatocellular carcinoma and mortality. However, with the advent of first- and second-generation direct-acting antivirals, genotype 3 can be treated effectively. Additionally, these new drugs are well tolerated by patients and have significantly fewer side effects compared to ribavirin and interferon-based regimens. However, while great strides have been made in overcoming biological barriers, our next challenge lies in overcoming economic and financial obstacles if we are to eradicate HCV genotype 3. Herein, we review the clinical features associated with HCV genotype 3, current and emerging treatment regimens, and challenges associated with treatment. |
format | Online Article Text |
id | pubmed-6102453 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Hellenic Society of Gastroenterology |
record_format | MEDLINE/PubMed |
spelling | pubmed-61024532018-09-01 Hepatitis C virus genotype 3: clinical features, current and emerging viral inhibitors, future challenges Shahnazarian, Vahe Ramai, Daryl Reddy, Madhavi Mohanty, Smruti Ann Gastroenterol Review Article Hepatitis C virus (HCV) represents a global burden on healthcare that affects over 150 million people worldwide. In the past, HCV genotype 3 was considered difficult to treat relative to other genotypes. Genotype 3 has been associated with a higher rate of complications, including fatty liver disease, fibrosis, hepatocellular carcinoma and mortality. However, with the advent of first- and second-generation direct-acting antivirals, genotype 3 can be treated effectively. Additionally, these new drugs are well tolerated by patients and have significantly fewer side effects compared to ribavirin and interferon-based regimens. However, while great strides have been made in overcoming biological barriers, our next challenge lies in overcoming economic and financial obstacles if we are to eradicate HCV genotype 3. Herein, we review the clinical features associated with HCV genotype 3, current and emerging treatment regimens, and challenges associated with treatment. Hellenic Society of Gastroenterology 2018 2018-06-04 /pmc/articles/PMC6102453/ /pubmed/30174390 http://dx.doi.org/10.20524/aog.2018.0281 Text en Copyright: © Hellenic Society of Gastroenterology http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Shahnazarian, Vahe Ramai, Daryl Reddy, Madhavi Mohanty, Smruti Hepatitis C virus genotype 3: clinical features, current and emerging viral inhibitors, future challenges |
title | Hepatitis C virus genotype 3: clinical features, current and emerging viral inhibitors, future challenges |
title_full | Hepatitis C virus genotype 3: clinical features, current and emerging viral inhibitors, future challenges |
title_fullStr | Hepatitis C virus genotype 3: clinical features, current and emerging viral inhibitors, future challenges |
title_full_unstemmed | Hepatitis C virus genotype 3: clinical features, current and emerging viral inhibitors, future challenges |
title_short | Hepatitis C virus genotype 3: clinical features, current and emerging viral inhibitors, future challenges |
title_sort | hepatitis c virus genotype 3: clinical features, current and emerging viral inhibitors, future challenges |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6102453/ https://www.ncbi.nlm.nih.gov/pubmed/30174390 http://dx.doi.org/10.20524/aog.2018.0281 |
work_keys_str_mv | AT shahnazarianvahe hepatitiscvirusgenotype3clinicalfeaturescurrentandemergingviralinhibitorsfuturechallenges AT ramaidaryl hepatitiscvirusgenotype3clinicalfeaturescurrentandemergingviralinhibitorsfuturechallenges AT reddymadhavi hepatitiscvirusgenotype3clinicalfeaturescurrentandemergingviralinhibitorsfuturechallenges AT mohantysmruti hepatitiscvirusgenotype3clinicalfeaturescurrentandemergingviralinhibitorsfuturechallenges |